By Dr Chris Haqq (Elicio Therapeutics)2024-07-18T10:00:01
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-26T09:05:00Z
Contributor Thomas Clozel M.D., By Drug Target Review
2026-05-19T09:46:00
Contributor Dr Nitza Thomasson
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, By Drug Target Review
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
Site powered by Webvision Cloud